U.K. based research driven pharmaceutical leader, AstraZeneca has recently struck a commercial deal with the reputed Japanese firm Takeda to co-develop an antibody therapy for Parkinson’s disease. Takeda has inked a deal worth USD 400 million, cite reliable sources. The FTSE 100 giant has teamed up with the Japanese drug maker to usher in an innovative medicine named Medi1341 in the pharmaceutical market. The pact is one among the latest partnerships of AstraZeneca with other drug makers, as the British firm seeks to raise funds for its upcoming pipeline of priority drug development projects related to oncology and cardiovascular therapies. It has been also reported that the Phase 1 clinical trials of this medicine are set to come aboard somewhere around the second half of this year.
Under the terms of the deal, it has been decided that both the firms will shoulder the development and commercial costs of the project, with revenues being shared correspondingly. Reportedly, AstraZeneca would spearhead Phase 1 development of the antibody (Medi134), while Takeda has claimed to take charge of the future development clinical activities. The deal is deemed to provide an impetus to AstraZeneca’s oncology business after it faced a major blow when the first round of their lung cancer trial, "Mystic trial" failed miserably last month.
The Japanese pharmaceutical giant, Takeda has a long track record in neurology, while for AstraZeneca, it has been a lower priority area. As per expert opinions, this deal comes as a profound strategic move by the British biopharmaceutical firm as it is seeking to exploit the untapped potentials of the neuroscience department. This is quite evident by its announcement regarding its profound agreement with the Boston-based company Berg, in parallel with the current deal with Takeda, to integrate artificial intelligence in the treatment of Parkinson’s disease.
Despite steady advancements in the diagnostic and therapeutic model, Parkinson’s disease continues to remain one of the burdensome challenges for the therapeutic discovery. Though it is yet to see how the commercialization of this breakthrough drug brings fortune back to AstraZeneca, it is no more a supposition that of MEDI1341 will undoubtedly prove to be beneficial for the people suffering from Parkinson’s disease across the globe. With the amalgamation of the scientific expertise of both these leading pharma firms, sharing both the risks and the development costs of the medicine, this neurological disorder may find the most suitable treatment sooner than anticipated by the medical fraternity.
Satarupa develops content for Market Size Forecasters. An electrical engineer by qualification, she worked for two years in the electrical domain before switching her professional genre. Following her childhood passion, she opted for a career in writing and now pens down articles pertaining to marke...